ARTICLE | Company News
AureoGen Biosciences, Merck deal
February 29, 2016 8:00 AM UTC
AureoGen granted Merck exclusive rights to develop and commercialize preclinical derivatives of aureobasidin A to treat infectious disease, including systemic fungal infections. Merck will also have e...